Artivion, Inc. $AORT Stake Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in Artivion, Inc. (NYSE:AORT) by 5.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 376,052 shares of the company’s stock after purchasing an additional 17,860 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.88% of Artivion worth $9,243,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legacy Advisors LLC bought a new stake in shares of Artivion during the 1st quarter worth about $28,000. MCF Advisors LLC raised its holdings in Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after purchasing an additional 614 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Artivion during the fourth quarter worth approximately $64,000. Raymond James Financial Inc. acquired a new stake in Artivion in the fourth quarter worth approximately $275,000. Finally, Natixis Advisors LLC boosted its stake in Artivion by 16.4% during the 1st quarter. Natixis Advisors LLC now owns 12,615 shares of the company’s stock valued at $310,000 after purchasing an additional 1,777 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Artivion news, SVP Marshall S. Stanton sold 26,132 shares of the firm’s stock in a transaction on Friday, June 13th. The shares were sold at an average price of $28.44, for a total value of $743,194.08. Following the sale, the senior vice president directly owned 79,200 shares in the company, valued at $2,252,448. This trade represents a 24.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John E. Davis sold 10,802 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the transaction, the insider owned 208,778 shares in the company, valued at $9,117,335.26. This represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 87,790 shares of company stock worth $3,190,959. 8.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AORT shares. Canaccord Genuity Group raised their target price on Artivion from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Oppenheimer reissued an “outperform” rating on shares of Artivion in a report on Friday, August 8th. Stifel Nicolaus lifted their price objective on shares of Artivion from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Needham & Company LLC increased their target price on shares of Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday. Finally, Citizens Jmp upgraded shares of Artivion to a “strong-buy” rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $40.63.

Artivion Stock Performance

AORT stock opened at $43.53 on Tuesday. The firm has a 50 day simple moving average of $33.95 and a 200 day simple moving average of $28.92. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $45.07. The stock has a market cap of $2.05 billion, a P/E ratio of -103.64 and a beta of 1.64. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.Artivion’s revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.